A large observational study suggested that ACE-inhibitor (ACEI)/Angiotensin II receptor blocker (ARB) therapy at least did not increase susceptibility to COVID-19 or worsen the outcome of COVID-19 patients [52]. The gene discussed is ACE; the disease is COVID-19.